

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-101159-PIP01-23

Scope of the Application

Active Substance(s)

MK 2870- Humanised IgG1 monoclonal antibody against TROP2, conjugated to a topoisomerase I inhibitor belotecan-derivative

Condition(s)

Treatment of lung cancer, Treatment of cervical cancer, Treatment of ovarian cancer, Treatment of endometrial cancer, Treatment of gastric cancer, Treatment of breast cancer

Pharmaceutical Form(s)

All pharmaceutical forms

Route(s) of Administration

All routes of administration

Name / Corporate name of the PIP applicant

Merck Sharp & Dohme (UK) Ltd.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Merck Sharp & Dohme (UK) Ltd. submitted to the licensing authority on 22/09/2023 14:36 BST an application for a Waiver

The procedure started on 15/07/2024 13:14 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Final Decision Letter

MHRA-101159-PIP01-23

Of 17/07/2024 14:50 BST

On the adopted decision for MK 2870- Humanised IgG1 monoclonal antibody against TROP2, conjugated to a topoisomerase I inhibitor belotecan-derivative (MHRA-101159-PIP01-23) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed conditions.

This decision applies to a Waiver for MK 2870- Humanised IgG1 monoclonal antibody against TROP2, conjugated to a topoisomerase I inhibitor belotecan-derivative, All pharmaceutical forms , All routes of administration .

This decision is addressed to Merck Sharp & Dohme (UK) Ltd., 120 Moorgate, London, UNITED KINGDOM, EC2M 6UR

ANNEX I

1. Waiver

1.1 Condition:

Treatment of lung cancer Treatment of gastric cancer Treatment of cervical cancer Treatment of ovarian cancer Treatment of breast cancer Treatment of endometrial cancer The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 18 years of age. Pharmaceutical form(s): All pharmaceutical forms Route(s) of administration: All routes of administration Reason for granting waiver: On the grounds the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s)

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not applicable.

2.2 Indication(s) targeted by the PIP:

Not applicable.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not applicable.

2.4 Pharmaceutical Form(s):

Not applicable.

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	

